INITIAL EXPERIENCE WITH AMSA AS SINGLE AGENT TREATMENT AGAINST MALIGNANT LYMPHOPROLIFERATIVE DISORDERS

  • 1 January 1981
    • journal article
    • research article
    • Vol. 57  (3) , 614-616
Abstract
Thirty previously treated adults with lymphoma received AMSA [4''-9-acridinylamino-methanesulfon-M-anisidide] as single agent therapy. All patients had previously received adriamycin-containing chemotherapy regimens and failed to respond initially or responded, but subsequently relapsed. The dose used was 40 mg/m 2 i.v. daily .times. 3. For patients with compromised marrow reserve or elevated bilirubin, a 25% reduction was used. Ten of 30 patients achieved an objective response (3 CR [complete remission], 3 PR [partial remission], 4 < PR). Of the 3 patients achieving a complete remission, 2 with histiocytic lymphoma remain in remission and are currently off treatment at 14+ and 18+ mo. The response rate of AMSA correlated with the type of response to frontline therapy and with the number of previous relapses. CR on AMSA were only seen in patients who had achieved a CR on frontline treatment and who were treated on their 1st relapse. AMSA is an active drug against malignant lymphoma and deserves further investigation.